Latest news with #TatvaChintanPharmaChem
Mint
a day ago
- Business
- Mint
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 3 July 2025
Breakout stocks buy or sell: Indian equities ended in the red on Wednesday as investors continued profit-booking in financial stocks after a recent rally, with selling pressure extending to public sector banks. Despite hopes of a possible US-India trade agreement, market sentiment remained subdued. The Nifty 50 fell 0.38% to close at 25,443, while the Sensex declined by 287 points to end at 83,409. Broader market indices also slipped, with the Nifty Midcap 100 easing 0.14% and the Nifty Smallcap 100 losing 0.41%. Sumeet Bagadia, Executive Director at Choice Broking, believes that Indian stock market sentiment is positive but the Nifty 50 index is facing hurdle at 25,650 to 25,700 zone. Speaking on the outlook of Indian stock market, Bagadia said, ' On breaking this hurdle on a closing basis, we can expect the 50-stock index to touch 26,200 soon. On the lower side, Nifty today has immediate support at 25,500, whereas it has crucial support at 25,250 to 25,200 range. So, one should maintain stock-specific approach and look at those stocks that are looking strong on the technical chart. Looking at breakout stocks can be a good option." Sumeet Bagadia recommends five breakout stocks to buy today: Subros, Tatva Chintan Pharma Chem, Sharda Cropchem, Pocl Enterprises, and LT Foods. 1] Subros: Buy at ₹ 1003.1, target ₹ 1075, stop loss ₹ 965; 2] Tatva Chintan Pharma Chem: Buy at ₹ 997.4, target ₹ 1070, stop loss ₹ 960; 3] Sharda Cropchem: Buy at ₹ 844.8, target ₹ 905, stop loss ₹ 815; 4] Pocl Enterprises: Buy at ₹ 897.85, target ₹ 965, stop loss ₹ 865; 5] LT Foods: Buy at ₹ 494.75, target ₹ 530, stop loss ₹ 477. Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions.
Business Standard
05-05-2025
- Business
- Business Standard
Tatva Chintan Pharma slides as Q4 PAT drops 89% YoY to Rs 1 cr
Tatva Chintan Pharma Chem declined 2.85% to Rs 684 after the company's consolidated net profit tanked 89.28% to Rs 1.03 crore in Q4 FY25, compared with Rs 9.61 crore psoted in Q4 revenue from operations rose 9.76% to Rs 107.86 crore in Q4 FY25 as against Rs 98.26 crore posted in Q4 the quarter, profit before tax dropped 85.24% to Rs 2.02 crore, compared with Rs 13.69 crore recorded in corresponding quarter last expenses jumped 19.59% to Rs 106.56 crore in the March 2025 as against Rs 89.10 crore posted in March 2024. Cost of materials consumed stood at Rs 47.91 crore (up 10.36% YoY) while employee benefits expense was at Rs 14.04 crore (down 2.22% YoY) during the a full year basis, the companys net profit tumbled 81.18% to Rs 5.71 crore on 2.74% decline in revenue from operations to Rs 382.71 crore in FY25 over the board recommended a final dividend of Rs 1 per equity share for the financial year 2024-25. This shall be paid subject to the approval of the shareholders at the ensuing annual general meeting of the Chintan Pharma Chem is an integrated specialty chemical company, present across the value chain manufacturing phase transfer catalyst, structure directing agents, electrolyte salts and pharma & agrochemical intermediates and specialty by Capital Market - Live News
Business Standard
03-05-2025
- Business
- Business Standard
Tatva Chintan Pharma Chem consolidated net profit declines 89.28% in the March 2025 quarter
Sales rise 9.76% to Rs 107.86 crore Net profit of Tatva Chintan Pharma Chem declined 89.28% to Rs 1.03 crore in the quarter ended March 2025 as against Rs 9.61 crore during the previous quarter ended March 2024. Sales rose 9.76% to Rs 107.86 crore in the quarter ended March 2025 as against Rs 98.27 crore during the previous quarter ended March 2024. For the full year,net profit declined 81.19% to Rs 5.71 crore in the year ended March 2025 as against Rs 30.35 crore during the previous year ended March 2024. Sales declined 2.74% to Rs 382.71 crore in the year ended March 2025 as against Rs 393.50 crore during the previous year ended March 2024. Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 107.8698.27 10 382.71393.50 -3 OPM % 8.3015.88 - 8.9417.33 - PBDT 9.2919.92 -53 35.2469.17 -49 PBT 2.0313.69 -85 7.5843.57 -83 NP 1.039.61 -89 5.7130.35 -81
